Drug Trial Radar · NCT06337032
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Aug 27, 2024
Primary completion
Jun 2027
Study completion Mar 2034
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events. The primary objectives of this study are as follows: * To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment. * To evaluate the safety of the study drug(s) in participants with HIV-1.
Conditions
- HIV-1-infection
Interventions
F/TAF (High Dose Tablet)Drug
200/25 mg fixed-dose combination (FDC) tablet administered orally
F/TAF (Low Dose Tablet)Drug
200/10 mg FDC tablet administered orally
F/TAF (Lowest Dose Tablet)Drug
120/15 mg FDC tablet administered orally
F/TAF (High Dose TOS)Drug
60/7.5 mg tablet for oral suspension (TOS) administered orally
F/TAF (Low Dose TOS)Drug
30/3.75 mg TOS administered orally
F/TAF (Lowest Dose TOS)Drug
15/1.88 mg TOS administered orally
E/C/F/TAFDrug
150/150/200/10 mg tablet administered orally
E/C/F/TAF (Low Dose)Drug
90/90/120/6 mg tablet administered orally
Cobicistat (High Dose)Drug
150 mg tablet administered orally
Cobicistat (Low Dose)Drug
90 mg tablet administered orally
Cobicistat (TOS)Drug
30 mg TOS administered orally
B/F/TAF (High Dose)Drug
50/200/25 mg FDC tablet administered orally
B/F/TAF (Low Dose)Drug
30/120/15 mg FDC tablet administered orally
B/F/TAF (High Dose TOS)Drug
15/60/7.52 mg TOS administered orally
B/F/TAF (Low Dose TOS)Drug
7.5/30/3.76 mg TOS administered orally
B/F/TAF (Lowest Dose TOS)Drug
3.76/15/1.88 mg TOS administered orally
3rd ARV AgentDrug
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country
Nucleos(t)ide reverse transcriptase inhibitors (NRTI)Drug
NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC)
ATVDrug
Administered according to the prescribing information
DRVDrug
Administered according to the prescribing information
Lopinavir Boosted with ritonavir (LPV/r)Drug
Administered according to the prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the StudyTime frame: Up to 2.8 Years
Locations
17 sites in 6 countries. Site status is shown where the registry gives one.
Helios Salud
Buenos Aires, Argentina · Completed
Hospital del Niño
Panama City, Panama · Completed
University of Stellenbosch
Cape Town, South Africa · Recruiting
Enhancing Care Foundation
Durban, South Africa · Recruiting
WITS RHI Research Centre
Johannesburg, South Africa · Recruiting
Rahima Moosa Mother and Child Hospital
Johannesburg, South Africa · Recruiting
Be Part Yoluntu Centre
Paarl, South Africa · Recruiting
The Aurun Institute
Pretoria, South Africa · Recruiting
Perinatal HIV Research Unit
Soweto, South Africa · Recruiting
Faculty of Medicine - Mahidol University
Bangkok Noi, Thailand · Active not recruiting
Khon Kaen University
Khon Kaen, Thailand · Active not recruiting
Joint Clinical Research Centre
Kampala, Uganda · Recruiting
MU-JHU Research Collaboration/MU-JHU Care Ltd
Kampala, Uganda · Recruiting
Baylor College of Medicine
Kampala, Uganda · Recruiting
Strengthening Institutional Capacity for Research Administration (SICRA)
Kampala, Uganda · Recruiting
Africa Medical and Behavioral Sciences Organisation
Masaka, Uganda · Recruiting
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.